Connecticut Startup Uses Preserved Human Brains to Accelerate Drug Discovery

Bexorg, a medical startup based in Connecticut, is utilizing a specialized life-support system called BrainEx to revive metabolic functions in donated human brains. By supplying blood substitutes and oxygen while using anesthesia to suppress electrical activity, the company creates a state where the organ functions biologically without achieving consciousness. This process allows researchers to test experimental treatments for neurodegenerative conditions, including Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis, in a real human environment.

The company argues that this method is superior to computer simulations or animal testing because it accounts for the complex effects of genetics and environmental history. After a 24-hour window of metabolic activity, the brains are dissected into hundreds of pieces for detailed analysis. To scale these operations, Bexorg is developing a new facility featuring robotic arms capable of processing over 1,600 preserved brains annually.

The practical application of this technology is already moving toward the market through a partnership with Biohaven. Early data from 130 preserved brains allowed Biohaven to adjust drug dosages significantly, reducing the required amount by twenty times and potentially minimizing side effects before entering clinical trials. This suggests a path toward safer and more efficient human drug development.

Despite the potential breakthroughs, the project faces ethical scrutiny and technical limitations. Because the system uses artificial fluids and suppresses neural firing, it cannot detect risks like seizures. While Bexorg claims that donors' families are informed of the process, the company continues to refine the technology to extend the lifespan of the preserved organs from one day to two weeks.